Aligos Therapeutics(ALGS)
搜索文档
Aligos Therapeutics(ALGS) - 2020 Q4 - Annual Report
2021-03-23 00:00
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-39617 Aligos Therapeutics, Inc. (Exact name of Registrant as specified in its Charter) Delaware 82-4724808 (State or other jurisdicti ...
Aligos Therapeutics(ALGS) - 2020 Q3 - Quarterly Report
2020-11-26 06:21
Table of Contents Title of each classTrading Symbol(s) Name of each exchange on which registered Common Stock, par value, $0.0001 per share ALGS The Nasdaq Stock Market LLC (Nasdaq Global Select Market) Emerging growth company ☒ UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15( ...